NIKKEI 225
38,245.24 -28.81 (-0.08%) HANG SENG
18,155.28 +392.25 (+2.21%) CRUDE OIL
79.52 +0.52 (+0.66%) GOLD FUTURES
2,327.80 +16.80 (+0.73%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,723.09 -2,329.50 (-4.85%)
Everest Medicines Limited (1952.HK)
| Previous close | 24.450 |
| Open | 24.450 |
| Bid | 25.250 x N/A |
| Ask | 25.500 x N/A |
| Day's range | 24.000 - 25.650 |
| 52-week range | 10.320 - 32.200 |
| Volume | |
| Avg. volume | 4,698,332 |
| Market cap | 8.08B |
| Beta (5Y monthly) | 2.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.920 |
| Earnings date | 28 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.83 |
PR NewswireEverest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced that the Hong Kong Department of Health had approved Nefecon® for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. Hong Kong marks the fourth region in Everest territories that Nefecon® received New Drug Application (NDA) approval after Singapore, Macau and mainland China. Nefecon® received full U.S. Food and Drug Administration (FDA) approval in December 2023.
PR NewswireEverest Medicines Announces Financial Results for Full Year Ended December 31, 2023
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced its financial results for the full year ended December 31, 2023, along with a corporate update.
PR NewswireEverest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Singapore Health Sciences Authority (HSA) has approved NEFEGAN® for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. NEFEGAN®, known in other Everest territories as Nefecon®, was the first ever treatment for IgAN full
